Mitsubishi Tanabe Pharma Corporation

108 articles with Mitsubishi Tanabe Pharma Corporation

• ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan

  1/18/2022

  ADC Therapeutics SA announced it has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications in Japan.

• Mitsubishi Tanabe Pharma America Showcases Breadth of ALS Research at Virtual 32nd International Symposium on ALS/MND

  12/1/2021

  Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations on amyotrophic lateral sclerosis (ALS) as part of the Motor Neurone Disease Association (MNDA) 32nd International Symposium on ALS/MND, being held virtually December 7-10.

• Mitsubishi Tanabe Pharma Canada Announces that Prince Edward Island has Added the Company's Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Formulary

  11/23/2021

  Mitsubishi Tanabe Pharma Canada, Inc., a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA®, an infusion treatment for amyotrophic lateral sclerosis, is now reimbursed through Prince Edward Island Pharmacare under Special Authorization.

• Mitsubishi Tanabe Pharma America Announces Presentations at 146th Annual Meeting of the American Neurological Association

  10/15/2021

  Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that two abstracts on amyotrophic lateral sclerosis (ALS) will be presented during the 146th Annual Meeting of the American Neurological Association (ANA2021), being held virtually October 17-19 .

• Mitsubishi Tanabe Pharma America Presents Analysis Examining Real-World Data on ALS Patient Disease Progression Milestones

  4/20/2021

  Mitsubishi Tanabe Pharma America, Inc. announced the presentation of an analysis of the timing of disease progression milestones among commercially insured amyotrophic lateral sclerosis patients treated with intravenous RADICAVA®.

• Post-Hoc Analysis of Phase 3 Study Examines Effect of Early Intervention with Edaravone on Survival and Disease Progression Milestone Events in ALS Patients

  3/18/2021

  Mitsubishi Tanabe Pharma America, Inc. announced a post-hoc analysis of its Phase 3 edaravone study reviewing the results of intravenous edaravone treatment on disease progression milestones and events among people with amyotrophic lateral sclerosis.

• Mitsubishi Tanabe Pharma America Presents Data on Impact of ALS Symptoms on Patients' Ability to Independently Conduct Daily Activities

  3/17/2021

   Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced findings from a new analysis evaluating the impact of symptom progression on the ability of people with amyotrophic lateral sclerosis (ALS)

• Mitsubishi Tanabe Pharma Canada Announces Treatment for Amyotrophic Lateral Sclerosis (ALS) is Now Available Through Newfoundland and Labrador Prescription Drug Program

  3/10/2021

  Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), announced today that RADICAVA ® (edaravone), an infusion treatment for amyotrophic lateral sclerosis (ALS), is now reimbursed through the Newfoundland and Labrador Prescription Drug Program (NLPDP) under Special Authorization.

• Mitsubishi Tanabe Pharma America Announces Establishment of NeuroDiscovery Lab Research Base in Cambridge, Mass.

  3/3/2021

  Mitsubishi Tanabe Pharma America, Inc. announced that Mitsubishi Tanabe Pharma Holdings America, Inc. plans to establish a new NeuroDiscovery Lab in the U.S. biotechnology hub of Cambridge, Mass.

• Mitsubishi Tanabe Pharma America Celebrates Five Years of Dedication to the ALS Community in the U.S.

  2/8/2021

  Mitsubishi Tanabe Pharma America, Inc. celebrated its five-year anniversary of being established in the United States in 2016.

• Mitsubishi Tanabe Pharma America and Aquestive Therapeutics Announce U.S. Licensing and Supply Deal for Riluzole Oral Film for ALS Treatment

  1/21/2021

  Mitsubishi Tanabe Pharma America, Inc. (MTPA) and Aquestive Therapeutics, Inc. (NASDAQ: AQST) today announced a licensing and supply deal for the U.S. rights to commercialize EXSERVAN ™  (riluzole), an oral film formulation of riluzole for the treatment of amyotrophic lateral sclerosis (ALS).  

• Mitsubishi Tanabe Pharma America Revises REFINE-ALS Biomarker Study Process to Enable Remote Participation

  1/7/2021

   Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced revisions to the REFINE-ALS biomarker study protocol to address the safety of people with amyotrophic lateral sclerosis (ALS) during the pandemic. The amendment gives patients the ability to consent to participate virtually, with the option to utilize telemedicine and

• Mitsubishi Tanabe Pharma America Announces Initiation of Open-Label Extension Study of Oral Edaravone in ALS

  12/22/2020

  - Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the initiation of a long-term safety extension study (MT-1186-A03) to the ongoing Phase 3 trial evaluating an investigational oral formulation of edaravone in patients with amyotrophic lateral sclerosis (ALS). The studies are sponsored by Mitsubishi Tanabe Pharma Dev

• Mitsubishi Tanabe Pharma America Announces Initiation of Postmarketing Commitment Study Assessing Daily Dosing of Oral Edaravone in Patients with ALS

  12/14/2020

   Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the initiation of a global clinical study exploring daily dosing of an investigational oral formulation of edaravone (MT-1186) in patients with amyotrophic lateral sclerosis (ALS). The study, sponsored by Mitsubishi Tanabe Pharma Development America, Inc. (MTDA), is

• Mitsubishi Tanabe Pharma America Presents Real-World Experience Outcomes During IV Edaravone Treatment at Virtual 31st International Symposium on ALS/MND

  12/11/2020

  Mitsubishi Tanabe Pharma America, Inc. (MTPA) and Soleo Health today announced a virtual poster presentation reviewing the analysis of real-world experience outcomes of treatment with RADICAVA ®  (edara

• Mitsubishi Tanabe Pharma America Announces Presentations of ALS Data at Virtual 31st International Symposium on ALS/MND

  12/3/2020

   Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced three amyotrophic lateral sclerosis (ALS) presentations as part of the Motor Neurone Disease Association (MNDA) 31 st International Symposium on ALS/MND, which is being held virtually December 9-11 .

• Post-Hoc Analysis of ALS Treatment Study Looks at Multiple Staging Systems

  11/30/2020

  Mitsubishi Tanabe Pharma America, Inc. announced results from a post-hoc analysis that examined the use of clinical staging systems to measure disease progression in amyotrophic lateral sclerosis, based on data from an edaravone Phase 3 trial.

• Mitsubishi Tanabe Pharma America Announces the Global Phase 3 Study of Oral Edaravone for ALS has Completed Enrollment

  11/9/2020

  Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that patient enrollment has been completed for the global Phase 3 open-label study evaluating the long-term safety and tolerability of an investigational oral suspension formulation of edaravone (MT-1186) in patients with amyotrophic lateral sclerosis (ALS). The study

• Mitsubishi Tanabe Pharma America Celebrates ALS Caregiver & Screenwriter Featured In MDA Kevin Hart Kids Telethon

  10/27/2020

  Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that Aleia Kristene Asbey , aspiring screenwriter and participant in the ALSO US ™  caregiver program for teen

• Mitsubishi Tanabe Pharma America Announces Presentations At Northeast Amyotrophic Lateral Sclerosis 19th Annual Meeting

  9/30/2020

   Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced four presentations on amyotrophic lateral sclerosis (ALS) will be shared as part of the Northeast Amyotrophic Lateral Sclerosis (NEALS) 19 th Annual Meeting, being held virtually Sept. 30 – Oct. 1, 2020 . The data provide deeper insight into U.S. experience wit